{
  "docId": "019dd923-622c-750b-8b9b-7e7228555e88",
  "docSlug": "36c903ba19aa",
  "documentTitle": "Allergan, Inc. (AGN)",
  "authorId": "01_Pershing_Square",
  "authorName": "William Ackman",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2014-04-22 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.70665085,
  "pageNumber": 18,
  "pageCount": 110,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "other",
  "function": "establish_context",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "Slide 18 of 110 from an SEC filing.",
  "elementsJson": [
    "headline_text",
    "callout_box",
    "bullet_list"
  ],
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9b-7e7228555e88/18",
  "deckHref": "/decks/019dd923-622c-750b-8b9b-7e7228555e88",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9b-7e7228555e88.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-7e7228555e88#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.82,
        "x": 0.09,
        "y": 0.13
      },
      "kind": "callout",
      "text": "In the four months since our initial contact with Valeant, we have performed significant due diligence on the company",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ba2f19a-d675-411a-8127-a2b455e1e04f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.82,
        "x": 0.09,
        "y": 0.22
      },
      "kind": "list",
      "text": "On February 9th, 2014 we executed a confidentiality agreement with Valeant, which allowed us to conduct substantial due diligence",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "13316351-1825-45b6-95b7-cc6399e394fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.7,
        "x": 0.14,
        "y": 0.26
      },
      "kind": "list",
      "text": "In-person meeting with board of directors\nExtensive management interviews\nSelective local due diligence at the country level\nReview of parent and regional business plans\nReview of historical and projected organic growth by business unit and region\nReview of business development pipeline\nReview of R&D pipeline\nReview of global tax structure\nReview of bear thesis",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1d78bb51-1e11-42a8-a234-85caa36c15d9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.6,
        "x": 0.09,
        "y": 0.19
      },
      "kind": "list",
      "text": "Reviewed public company information for Valeant and Allergan",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4aa94fc5-0cac-4a75-85d6-a8d323df8cfe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.09,
        "y": 0.09
      },
      "kind": "title",
      "text": "Pershing Square Due Diligence on Valeant",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b72f8d9a-d940-4bc2-bd9f-882db4d82fcb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}